“The era of Progeria gene therapy has arrived. Our hope is that SamPro-2 will give children and young adults with Progeria the longer, healthier lives they...
Ascidian and Forge announce a strategic partnership to advance the development and manufacturing of ACDN-01, Ascidian’s lead retinal program for the...
“Forge’s AAV-specific manufacturing expertise and platform technologies give us confidence in a smooth path forward in the development of AVST-101,” said...
Fractyl Health will leverage Forge’s FUEL™ platform to manufacture AAV for Rejuva, Fractyl's pancreatic gene therapy platform for patients with obesity and...